Effects of Metformin, Pioglitazone, and Silymarin Treatment on Non-Alcoholic Fatty Liver Disease: A Randomized Controlled Pilot Study

@inproceedings{Hajiaghamohammadi2012EffectsOM,
  title={Effects of Metformin, Pioglitazone, and Silymarin Treatment on Non-Alcoholic Fatty Liver Disease: A Randomized Controlled Pilot Study},
  author={Ali Akbar Hajiaghamohammadi and Amir M Ziaee and Sonia Oveisi and Homa Masroor},
  booktitle={Hepatitis monthly},
  year={2012}
}
BACKGROUND Nonalcoholic fatty liver disease (NAFLD) is one of the most common reasons of enzyme increase in liver. In About 10 percent of patients with NAFLD, the disease progresses toward Non Alcoholic Steatohepatitis (NASH) and about one third of them may progress toward cirrhosis, liver dysfunction, and even hepatocellular carcinoma. OBJECTIVES According to high prevalence of NAFLD and the fact that there is no consensus on treatment of this disease, the aim of this study was to assess the… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS
17 Citations
18 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 17 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 18 references

A placebo-controlled trial of silymarin in patients with nonalcoholic fatty liver disease

  • SJ Hashemi, E Hajiani, E. Haidari Sardabi
  • Hepat Mon
  • 2009
2 Excerpts

The efficacy of silymarin in decreasing transaminase activities in non-alcoholic fatty liver disease: A randomized controlled clinical tria

  • AA Hajaghamohammadi, A Ziaee, R. Rafiei
  • Hepat Mon
  • 2008
1 Excerpt

Similar Papers

Loading similar papers…